68% of adults with T1D
who did not screen say they regret not taking an autoantibody test
to better understand their risk of developing T1D.
- For U.S. Residents Only
-
Destinado únicamente para residentes
de Estados Unidos -
WHY SCREEN AND KNOW SOONER
Screening for type 1 diabetes today will help spot symptoms early and reduce the risk of dangerous complications.
Why should you
SCREEN?
SCREEN?
Type 1 diabetes (T1D) can be spotted with screening before symptoms are noticeable. As many as 40% of people have no idea they have T1D until they experience a life-threatening event that requires hospitalization. So don't wait. Screening could help you or a loved one:
KNOW THE OPTIONS
Advancements in treatment and management of autoimmune type 1 diabetes may offer ways to help. Talk to your or your loved one’s doctor about what could come next. You or your loved one may be able to participate in a clinical trial or explore available treatment options.
LEARN THE SYMPTOMS OF TYPE 1 DIABETES
By knowing if you or your loved one is in the early stages of autoimmune type 1 diabetes, you can be better prepared to recognize symptoms when they appear. This can help you understand what's ahead and lower the risk of potentially life-threatening complications like diabetic ketoacidosis (DKA) with a doctor's help.
PREPARE FOR WHAT'S AHEAD
Knowing if you or your loved one has early-stage type 1 diabetes can give you time to plan ahead. Living with type 1 diabetes means taking on new responsibilities, and there is a learning curve that comes with managing it. Getting ahead of insulin dependence can help you:
-
develop the skills needed to manage type 1 diabetes
-
keep up with treatment and management options your doctor can offer
-
find the right care team and T1D support community to help
Real People, Real Reasons to Screen
Waiting to screen - either because you didn't know you could or
because it wasn't a priority - can have a major impact on your health.
Transcript
WHAT REAL PEOPLE WITH T1D
WISH YOU
KNEW
ABOUT
SCREENING
WISH YOU
KNEW
ABOUT
SCREENING
Each year, around
64,000 Americans are diagnosed with
type 1 diabetes (T1D). Although T1D is not preventable, findings
from surveys conducted by Beyond Type 1 and commissioned by Sanofi
show that knowing sooner about the risk of developing diabetes can
have a big impact.
To help understand whether knowing sooner about the risk of developing T1D could have a positive impact on a person’s overall well-being, a survey of 2,000 adults and caregivers of children with T1D was conducted.
To help understand whether knowing sooner about the risk of developing T1D could have a positive impact on a person’s overall well-being, a survey of 2,000 adults and caregivers of children with T1D was conducted.
The findings:
WHAT REAL PEOPLE WITH T1D
WISH YOU
KNEW
ABOUT
SCREENING
WISH YOU
KNEW
ABOUT
SCREENING
WHO WAS
SURVEYED?
SURVEYED?
- 1,000 adults living with type 1 diabetes
- 1,000 caregivers of children with type 1 diabetes
*Research commissioned by Sanofi
Adults with type 1 diabetes (T1D) and caregivers regret not learning
sooner about the risk of developing T1D
93% of caregivers
say they wish they had learned about their loved one's risk of
developing T1D prior to their diagnosis.
“Not knowing” can have major financial, emotional and social burdens
50% of adults with T1D
spent at least $5,000 on emergency care for their T1D symptoms
before or during their diagnosis, with nearly
1 in 4
(24%) spending at least $10,000.
64% of adults with T1D
say their emotional health declined when they first received their
diagnosis; 61% said knowing
about their risk sooner would have helped with these feelings.
71% of adults with T1D
made changes to some of their interests or plans after receiving
their diagnosis. 37% of this group say they would not have done so
if they had known sooner about their risk of developing T1D.
Knowing sooner can have an impact, particularly on how adults with
T1D and caregivers live their lives
79% of adults with T1D and 83% of caregivers
changed how they lived their life when they received their
diagnosis.
Had they screened and known sooner about their T1D diagnosis,
adults with T1D say they may have:
Screening is uncommon, due largely to a lack of awareness and
perceived barriers
Only 14% of adults with T1D
say they were screened with an autoantibody test prior to their
diagnosis to see if they were at risk of developing the disease.
Among those who did not screen,
72% of adults with T1D and 66% of caregivers
say they were unaware that a T1D autoantibody test was even
available.
Only 5% of adults with T1D were aware that the autoantibody test was
available but chose not to take it.
Nearly all adults with T1D and caregivers recommend early screening
for type 1 diabetes
92% of adults with T1D
say they would recommend friends and family members get an early
autoantibody test for T1D to understand their risk of developing
the disease.
This jumps to
96% for caregivers
*This research was conducted by Wakefield Research via two survey
instruments -- one among 1,000 US adults with type 1 diabetes and a second
among 1,000 US caregivers to those under the age of 18 years with type 1
diabetes.
Background & Methodology
This research was conducted by Wakefield Research
(www.wakefieldresearch.com) via two survey instruments—one among 1,000
US adults with type 1 diabetes and a second among 1,000 US caregivers
to those under the age of 18 years with type 1 diabetes, between March
15th and March 29th, 2024, using an email invitation and an online
survey.
Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample. The distribution of key demographic characteristics for both audiences were monitored during data collection, to align with available information provided by the CDC and NIH.
Beyond type 1 and Sanofi do not provide medical advice, diagnosis, or treatment—information is provided for educational purposes only. Your doctor is the best source of health information. Talk to your doctor if you have any questions about your health or treatment. The survey was conducted anonymously. Respondents were not made aware of the survey sponsor, and no personally identifiable information (PII) about the respondents was shared with the survey sponsor. Respondents were incentivized for their participation, in keeping with best practice for opinion research.
Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample. The distribution of key demographic characteristics for both audiences were monitored during data collection, to align with available information provided by the CDC and NIH.
Beyond type 1 and Sanofi do not provide medical advice, diagnosis, or treatment—information is provided for educational purposes only. Your doctor is the best source of health information. Talk to your doctor if you have any questions about your health or treatment. The survey was conducted anonymously. Respondents were not made aware of the survey sponsor, and no personally identifiable information (PII) about the respondents was shared with the survey sponsor. Respondents were incentivized for their participation, in keeping with best practice for opinion research.
